The Food and Drug Administration found an Akorn facility violated current good manufacturing practice regulations. The drugmaker’s stock has taken a hit due to the warning letter.
Akorn receives warning letter from FDA
The Food and Drug Administration found an Akorn facility violated current good manufacturing practice regulations. The drugmaker’s stock has taken a hit due to the warning letter.